钠-葡萄糖共转运蛋白 2 抑制剂对射血分数降低的心力衰竭患者和射血分数保留的心力衰竭患者估算血浆容量的影响。
Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction.
机构信息
Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Center of Nuclear Medicine, Faculty Hospital Bulovka, Prague, Czech Republic.
出版信息
Clin Cardiol. 2024 Jul;47(7):e24303. doi: 10.1002/clc.24303.
BACKGROUND
The increased diuresis after sodium-glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients.
HYPOTHESIS
We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration.
PATIENTS AND METHODS
We analyzed the early- and long-term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.
RESULTS
The ePV change was -22.56% between baseline and 1 month, and -37.60% between baseline and 12 months follow-up in a patient with HFrEF, and -6.18% and -16.40% in a patient with HFpEF, respectively.
CONCLUSION
The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.
背景
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）增加利尿作用与 2 型糖尿病患者估计血浆容量（ePV）减少有关。
假说
我们假设 SGLT2i 对 ePV 的早期影响可以通过血液浓缩标志物的变化来监测。
患者和方法
我们分析了心力衰竭和射血分数降低（HFrEF）的非糖尿病患者和心力衰竭和射血分数保留（HFpEF）的非糖尿病患者中 SGLT2i 恩格列净对 ePV 的早期和长期影响。通过 Duarte 公式从血红蛋白和血细胞比容水平计算 ePV，通过 Strauss 公式计算 ePV 变化。
结果
在 HFrEF 患者中，ePV 变化分别为基线至 1 个月时为-22.56%，基线至 12 个月随访时为-37.60%，在 HFpEF 患者中分别为-6.18%和-16.40%。
结论
心力衰竭患者 SGLT2i 对 ePV 的早期影响可以通过血液浓缩标志物来监测。
Zotero 插件